You are here
Disease modifying therapies
Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab
Julie Hejgaard Laursen, Helle Bach Søndergaard, Per Soelberg Sørensen, Finn Sellebjerg, Annette Bang Oturai
Multiple Sclerosis and Related Disorders, November 2016, Pages 169 - 173
Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis
Mark S. Freedman, Xavier Montalban, Aaron E. Miller, Catherine Dive-Pouletty, Steven Hass, Karthinathan Thangavelu, Thomas P. Leist
Multiple Sclerosis and Related Disorders, November 2016, Pages 204 - 212
Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis
Ying Liu, Timothy Vollmer, Eva Havrdova, Katherine Riester, Andrew Lee, Glenn Phillips, Ping Wang, Guido Sabatella
Multiple Sclerosis and Related Disorders, January 2017, Pages 18 - 24
Tuncay Gündüz, Murat Kürtüncü, Mefkure Eraksoy
Multiple Sclerosis and Related Disorders, January 2017, Pages 1 - 3
- Medicine, Volume 44, Issue 9, September 2016, Pages 537–541
- Merck has financed the symposium, however the opinions and recommendations represent the independent views of the speakers and do not...
- Question 1: Is there an unmet need for a therapy without continuous immunosuppression? The speakers compare and contrast the ‘old’...
- MS is associated with a high disease-burden, in particular, treatment and monitoring burdens have increased with new therapies. Dr Wiendl...
Part 4 of 2016 Symposium: Current and future therapies – Are we getting closer to addressing the unmet needs?Over the past 10 years many new therapies have been approved. Dr Schippling reviews the newer therapies: inhibitors of immune-cell...
- The Grant for Multiple Sclerosis Innovation (GMSI) Awards event was held on September 15, 2016 at the ECTRIMS conference in...